Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Decoy Therapeutics Q3 2026 Results: Net Loss of $2.99M, Loss Widens

Decoy Therapeutics Inc. reported a net loss of $7.59 million for the nine months ended September 30, 2026, compared to a $3.54 million loss in the prior year period, driven by a significant increase in research and development expenses. The company recognized $535,059 in grant revenue during the period and maintains a cash balance of approximately $8.17 million as of September 30, 2026.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.30.0
Net income-3.0-0.9
EPS (diluted, $ a share)$-3.53$-21.76

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: DCOY. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Decoy Therapeutics Inc.: key numbers

Share price
$0.9010Close, Nov 16
Market cap
$2.15M
Shares outstanding
2.39MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Decoy Therapeutics Inc.

All →
5:02 PM ET 8-K
Capital Raise

Decoy Therapeutics Capital Raise of $3.85M

Decoy Therapeutics entered into a warrant inducement agreement with an institutional investor for the immediate cash exercise of 1,184,434 Series B Milestone Warrants at a reduced price of $3.25 per share. The transaction generated $3.85 million in gross proceeds and included the issuance of 2,368,868 new unregistered warrants to the holder. Proceeds are intended for working capital and general corporate purposes.

Value
$3.85M
Counterparty
institutional investor
5:01 PM ET 8-K
Shareholder Meeting

Decoy Therapeutics Shareholder Meeting

Decoy Therapeutics held a Special Meeting of Stockholders on September 14, 2026, where shareholders approved the issuance of common stock upon the exercise of Series A, B, and C Milestone Warrants. Stockholders also approved an amendment to the Certificate of Incorporation to reduce the number of authorized shares of common stock from 100 million to 90 million.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.